In Japan, patients diagnosed with late-onset or juvenile-onset progressive HL due to pathogenic variations in the ACTG1, CDH23, COCH, KCNQ4, TECTA, TMPRSS3, WFS1, EYA4, MYO6, MYO15A and POU4F3 genes, and who have progressed to severe-to-profound HL, are provided with medical support from the government throughout their life, and we aim to further our research and increase the number of genes for which late-onset progressive HL patient support is applicable. This evidence concerns the gene ACTG1 and Hodgkins lymphoma.